Recent Updates
Recently added Catalysts
HALO

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at...

Key Takeaway: SAN DIEGO , Nov. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET / 9:00 a.m. PT . Gregory I. Frost , Ph.D., President and Chief Executive O

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
2.9%
average across 3 past catalysts
Lead asset
Recombinant human hyaluronidase PH20
Phase 1 · Healthy

Full Press Release Details

SAN DIEGO , Nov. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET / 9:00 a.m. PT . Gregory I. Frost , Ph.D., President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com , and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
Last updated: Nov 26, 2013